Drug
Relamorelin clinical trials
Also written RM-131.
- studies test it
- 13
- open now
- 0
- in phase 3
- 5
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Studies
Open first, then newest update. How each study uses relamorelin is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03TerminatedPhase 3AllerganNCT03420781Written as Relamorelin
- Diabetic Gastroparesis Study 05TerminatedPhase 3AllerganNCT03786380Written as Relamorelin 10 μg
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04TerminatedPhase 3AllerganNCT03383146Written as Relamorelin
- Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02TerminatedPhase 3AllerganNCT03426345Written as Relamorelin
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01TerminatedPhase 3AllerganNCT03285308Written as Relamorelin
- Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic GastroparesisCompletedPhase 2AllerganNCT02357420Written as Relamorelin
- Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic ConstipationCompletedPhase 2Motus Therapeutics, Inc.NCT01781104Written as RM-131
- Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia NervosaCompletedPhase 2Motus Therapeutics, Inc.NCT01642550Written as RM-131
- Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic GastroparesisCompletedPhase 2Motus Therapeutics, Inc.NCT01571297Written as RM-131
- A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic ConstipationTerminatedPhase 2Motus Therapeutics, Inc.NCT01955616Written as RM-131
- Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic GastroparesisCompletedPhase 1Motus Therapeutics, Inc.NCT01394055Written as RM-131
- Study to Evaluate the Effects of RM-131 in Patients With Chronic ConstipationCompletedPhase 1Motus Therapeutics, Inc.NCT02137642Written as RM-131
- Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy VolunteersCompletedPhase 1Motus Therapeutics, Inc.NCT02466711Written as Relamorelin
Codes
What other systems call relamorelin · ClinicalTrials.gg INT000139
- MeSH (NLM) C000593860relamorelinOne source NLM
- UNII (FDA) BIW199E18VRELAMORELINConfirmed FDA, NLM, Wikidata
- Wikidata Q21098925RelamorelinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152174RelamorelinOne source FDA
- DrugBank DB12678One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593860 | relamorelin | One source NLM |
| UNII (FDA) | BIW199E18V | RELAMORELIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098925 | Relamorelin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152174 | Relamorelin | One source FDA |
| DrugBank | DB12678 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.